Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤TN-401 receives FDA RMAT designation for PKP2-associated ARVC
- ➤Cash $66.8M funds planned operations into fourth quarter 2027
- ➤TN-201 and TN-401 additional clinical data and pivotal-trial updates expected by year end
- ➤Q3 net loss $18.9M, or $0.08 per share, versus $20.3M loss
- ➤TN-301 Phase 2 trial planned for second half of 2027
Expert Statements
Faraz Ali, Chief Executive Officer of Tenaya Therapeutics
“As we celebrate the tenth anniversary of Tenaya, we are entering one of the most important periods in the Company’s history”
Faraz Ali, Chief Executive Officer of Tenaya Therapeutics
“The forthcoming data updates from TN-201 and TN-401, together with regulatory feedback on potential pivotal development pathways, are expected to inform potential opportunities to advance these programs toward late-stage development.”
Faraz Ali, Chief Executive Officer of Tenaya Therapeutics
“We are also preparing to share our vision for TN-301’s potential and future clinical development.”
Faraz Ali, Chief Executive Officer of Tenaya Therapeutics
“Collectively, these milestones are expected to provide important clarity on the path forward for our portfolio and capital allocation decisions, defining the next phase of growth for Tenaya.”
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
TN-201 and TN-401 Program Updates on Upcoming Data Readouts and Regulatory Interactions for Pivotal Trial Planning Anticipated by Year-End
Get started
Create a free account to read the full story.